FIELD: biotechnology.
SUBSTANCE: invention presents: a monoclonal antibody or its binding fragment, which bind to domain 3 of human LAG-3, which have: in vitro activity ADCC, bind to activated human T-cells, where human LAG-3 binds to molecules of the main complex of human histocompatibility class II in the presence of the antibody or its binding fragment, while the presence of the antibody or its binding fragment allows human LAG-3 to perform a function of suppression of human T-cells. Nucleic acid molecules, an expression vector, a cell for the production of an antibody or its binding fragment, a method for the production of an antibody or its binding fragment, compositions for the treatment and prevention of a disease related to LAG-3-positive cells, a method for the treatment or prevention of an autoimmune disease in a patient, and a method for the treatment or prevention of transplant rejection in a patient are also disclosed.
EFFECT: invention allows for the production of a new monoclonal antibody or its binding fragment, which have high affinity to domain 3 of human LAG-3.
41 cl, 101 dwg, 11 ex
Title | Year | Author | Number |
---|---|---|---|
BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
ANTIBODY AGAINST LAG-3 | 2017 |
|
RU2744866C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
BISPECIFIC ANTIBODY | 2020 |
|
RU2814713C2 |
COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
ANTIBODY TO HUMAN CD73 | 2017 |
|
RU2754058C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO LAG-3 AND ITS USE | 2018 |
|
RU2771384C2 |
Authors
Dates
2022-10-06—Published
2017-09-07—Filed